Journal
ANNALS OF ONCOLOGY
Volume 32, Issue 1, Pages 23-33Publisher
ELSEVIER
DOI: 10.1016/j.annonc.2020.09.019
Keywords
chronic lymphocytic leukaemia; prognostic factors; individualised therapy; B-cell receptor inhibitors; BCL2 inhibitor; targeted treatment
Categories
Funding
- ESMO from central funds